Sep 26, 2023 8:30am EDT Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Sep 20, 2023 8:30am EDT Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
Sep 11, 2023 7:00am EDT Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Aug 30, 2023 8:30am EDT Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
Aug 03, 2023 8:30am EDT Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
Jun 21, 2023 8:30am EDT Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
Jun 01, 2023 8:30am EDT Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
